Danish Chemicals Stock News

Methanex, Ørsted and Exolum have launched the U.K.’s first commercially ready biomethanol storage and marine bunkering service at the Port of Immingham, providing low‑carbon fuel for shipping and supporting Ørsted’s North Sea offshore wind maintenance vessels. The project shows how existing fuel infrastructure can be re‑tooled for green fuels, offering a practical pathway to cut domestic shipping emissions that currently exceed those from buses, trains and domestic aviation combined in the...

Zealand Pharma (CPSE:ZEAL) has drawn attention after reporting full year 2025 results, with sales of DKK 9,214.86 million and net income of DKK 6,455.01 million, compared to a net loss a year earlier. See our latest analysis for Zealand Pharma. Despite the strong full year 2025 results and recent trial update for ZP9830, the share price return has been weak over shorter periods, with a 30 day share price return showing a decline of 7.77% and a 1 year total shareholder return showing a decline...

Zealand Pharma reported positive topline Phase 1a data for Kv1.3 channel blocker ZP9830 from a single ascending dose trial. The study evaluated safety, tolerability, and pharmacological effects of ZP9830 in first in human testing. The company highlighted immunomodulatory potential based on the observed pharmacological effects in healthy volunteers. For Zealand Pharma, ticker CPSE:ZEAL, this update lands after a mixed share price record, with the stock at DKK382.8 and a 49.2% decline over...

Carlsberg triggered Carlsberg (CPSE:CARL B) has come into focus after a strong recent run in the share price, prompting investors to reassess how the brewer’s current valuation lines up with its fundamentals. See our latest analysis for Carlsberg. At a share price of DKK991.8, Carlsberg’s 30-day share price return of 17.26% and 90-day return of 29.41% suggest building momentum, while its 1-year total shareholder return of 20.83% points to solid medium term gains. If this kind of move has you...

GN Store Nord (CPSE:GN) shares have been reacting to the company’s full year 2025 earnings, in which both sales and net income were lower than the prior year. This has put renewed attention on the stock’s recent performance. See our latest analysis for GN Store Nord. The full year 2025 earnings release appears to have been a key catalyst for the share price, with the stock posting a 1 day share price return of 1.05% and a 7 day share price return of 1.45% after a softer 30 day share price...

Genmab (CPSE:GMAB) has wrapped up FY 2025 with fourth quarter revenue of US$1.1b and basic EPS of US$0.50, rounding out a trailing twelve month EPS of US$15.5 on revenue of US$3.7b. The company has seen quarterly revenue move from US$715 million in Q1 2025 to US$1.1b in Q4, alongside EPS ranging from US$3.06 in Q1 to US$6.51 in Q3 and US$0.50 in Q4. This sets up a results season where investors are likely to focus on how these shifts flow through to margins and the durability of its earnings...

NKT (CPSE:NKT) has drawn fresh attention after announcing an exclusive power cable partnership with German grid operator Mainova. The agreement runs to 2033 and supports Frankfurt’s long term electricity network upgrade and electrification needs. See our latest analysis for NKT. Alongside this Mainova deal and recent news such as the power purchase agreement with Uniper and the upcoming CFO change, NKT’s 1 year total shareholder return of 64.04% and 5 year total shareholder return of 264.59%...

Q1 earnings snapshot and why it matters for shareholders Coloplast (CPSE:COLO B) has just reported first quarter results, with sales of DKK 7,043 million, net income of DKK 1,397 million, and basic earnings per share of DKK 6.2 from continuing operations. See our latest analysis for Coloplast. At a share price of DKK485.0, Coloplast has seen a 30 day share price return of 10.65% decline and a year to date share price return of 9.58% decline, while the 1 year total shareholder return of 36.64%...

Genmab A/S has released its full-year 2025 results, reporting revenue of US$3.72 billion versus US$3.12 billion in 2024 and net income of US$963 million, alongside 2026 guidance calling for higher revenue but a potentially lower operating profit range of US$0.9–1.4 billion. The earnings update also highlighted FDA approval of Abkinley in second-line follicular lymphoma and a broadened oncology pipeline, including new Phase 3 trials and assets gained through acquisitions, which together...

Ørsted A/S' ( CPH:ORSTED ) robust earnings report didn't manage to move the market for its stock. We did some digging...

H. Lundbeck (CPSE:HLUN B) is back in focus after reporting positive phase IIb data from the PROCEED trial of bocunebart, a potential migraine preventive therapy targeting patients with prior treatment failures. See our latest analysis for H. Lundbeck. The positive PROCEED data has come just days after Lundbeck reported full year 2025 results and proposed a higher dividend, and the stock has reacted with a 1 day share price return of 2.97% and 7 day share price return of 4.42%. That said, the...

Methanex and Ørsted (CPSE:ORSTED) have launched the U.K.'s first commercially ready biomethanol bunkering service at the Port of Immingham, giving investors a fresh data point on the company’s role in low carbon shipping fuels. See our latest analysis for Ørsted. That biomethanol bunkering launch comes after Ørsted’s recent full year 2025 earnings and a board change in early February, and it lands during a period of renewed share price momentum. The shares have a 30 day share price return of...

Aktieselskabet Schouw & Co. (CPSE:SCHO) shareholders approved the release of BioMar as an Original Guarantor under the company’s bond terms. The decision removes BioMar from its status as a Material Subsidiary in the bond documentation. The approval was granted by a majority vote of shareholders. Aktieselskabet Schouw & Co. (CPSE:SCHO) is a Danish industrial group with holdings across several sectors, and BioMar has been one of its key subsidiaries. The shareholder-backed decision to remove...

Most readers would already know that TORM's (CPH:TRMD A) stock increased by 9.3% over the past three months. Given that...

The market shrugged off Novo Nordisk A/S' ( CPH:NOVO B ) solid earnings report. We did some digging and believe...

Key Insights Zealand Pharma's significant retail investors ownership suggests that the key decisions are influenced by...

In early February 2026, Novo Nordisk reported full-year 2025 results showing higher annual sales and earnings, proposed a DKK 11.70 total dividend per share for 2025, authorized a DKK 15,000 million buyback, and released positive phase 3 REIMAGINE 2 data for its CagriSema combination in type 2 diabetes. At the same time, Novo Nordisk moved to protect its GLP-1 franchise by suing Hims & Hers over compounded obesity drugs and preparing new Wegovy vial formats, highlighting how intellectual...

A.P. Møller - Mærsk (CPSE:MAERSK B) has opened a major ground freight hub in Southern California. The new facility is intended to speed up regional deliveries and strengthen Maersk's North American logistics network. The hub focuses on improving service reliability and supply chain efficiency for customers. This development is expected to support faster turnaround times and broader distribution capabilities across the region. A.P. Møller - Mærsk, traded as CPSE:MAERSK B, is known primarily...

DSV A/S' ( CPH:DSV ) recent soft profit numbers didn't appear to worry shareholders, as the stock price showed...

The market was pleased with the recent earnings report from Carlsberg A/S ( CPH:CARL B ), despite the profit numbers...

Pandora’s higher dividend proposal and steady EPS catch investors’ attention Pandora (CPSE:PNDORA) shares have been in focus after the jewellery group paired its 2025 earnings report with a higher proposed dividend and solid basic and diluted earnings per share figures. See our latest analysis for Pandora. Despite the upbeat 2025 earnings and higher proposed dividend, Pandora’s recent share price performance has been weak, with a 90 day share price return of 30.55% decline and a 1 year total...

Regulatory milestone and why it matters for ALK-Abelló ALK-Abelló (CPSE:ALK B) is in focus after the European Medicines Agency’s CHMP issued a positive opinion supporting an extension of EURneffy’s marketing authorisation to include a 1 mg nasal adrenaline spray for children. This regulatory step, if converted into full European Commission approval, could broaden EURneffy’s eligible patient group across the EU, Iceland, Liechtenstein and Norway, giving investors another reference point when...

As European markets remain buoyant, with the STOXX Europe 600 Index reaching new highs and optimism about the eurozone economy prevailing, investors are keenly observing potential opportunities amid recent market volatility. In this context, identifying stocks that may be undervalued relative to their intrinsic worth can be a strategic approach for those looking to capitalize on market conditions where cyclical and value-oriented segments are gaining traction.

As the pan-European STOXX Europe 600 Index reaches new highs, optimism about the eurozone economy is helping to counterbalance recent market volatility. With inflation slowing faster than forecast and key interest rates remaining steady, investors are increasingly focusing on small-cap stocks that may offer unique opportunities in this evolving landscape. Identifying promising stocks often involves looking for companies with strong fundamentals and potential growth catalysts that align well...